atara biotherapeutics ebvallo

CRL, Atara

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is rated as a Buy.

Business Insider · 2d

Atara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL Issues

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence:

Reuters on MSN · 3d

US FDA puts clinical hold on Atara's trials for cancer cell therapies

Atara Biotherapeutics said on Tuesday the U.S. health regulator had placed a clinical hold on its trials for cancer cell therapies, sending the drug developer's shares down more than 4% in premarket trading.

Seeking Alpha on MSN · 3d

Atara extends losses after FDA clinical hold

Shares of Atara Biotherapeutics (NASDAQ:ATRA) continued to trade lower in the premarket on Tuesday after the U.S. Food and Drug Administration (FDA) slapped the cell therapy developer with a clinical hold,

Business Insider · 3d

Atara Biotherapeutics reports clinical hold placed on Ebvallo programs, ATA3219

Atara Biotherapeutics (ATRA) announced that the FDA has placed a clinical hold on Atara’s active investigational new drug, or IND,

FiercePharma3d

Atara's Ebvallo and pipeline candidate put on clinical hold in US after partner's failed plant inspection

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

3don MSN

Stifel cuts Atara Biotherapeutics target to $5, holds rating

Stifel analysts adjusted their outlook on Atara Biotherapeutics (NASDAQ:ATRA) stock, reducing the price target to $5 from the previous $10, while maintaining a Hold rating on the shares. The decision ...

BioSpace2d

FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...

Atara Biotherapeutics price target lowered to $5 from $10 at Stifel

Stifel lowered the firm’s price target on Atara Biotherapeutics (ATRA) to $5 from $10 and keeps a Hold rating on the shares after the FDA has ...

FiercePharma8d

Atara, Pierre Fabre hit a hurdle with Ebvallo in the US courtesy of manufacturing plant's shortfalls

As partners Atara Biotherapeutics and Pierre Fabre Laboratories work to grow the reach of their novel T-cell immunotherapy ...

Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/17.DwxO7Jta.js ...

Zacks.com on MSN7d

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate

Shares of Atara Biotherapeutics ATRA plunged 40.5% on Thursday after the FDA issued a complete response letter (CRL) against ...

Atara Biotherapeutics, Inc. Being Investigated on Behalf of Atara Biotherapeutics, Inc. Investors. Contact Levi & Korsinsky For Details

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results